Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Biogen inc. crawled time : 00:00 save search
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | News | $39.52 -0.13% 0.0% 2.8M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | $66.93 -0.57% -0.55% 3.8M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
Listeria Monocytogenes Infections Treatment Global Market Report 2024: Global Expansion in Listeria Monocytogenes Treatment Sector Predicted Amid Rising Foodborne Disease Incidence
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 290
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: -0.63%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
AZNCF | $140.15 3.58% -4.19% 560
|
Health Technology
|
| O: 0.87%
H: 0.21%
C: -2.23%
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
VRTX | $393.1 -0.27% -0.27% 620K
|
Health Technology
|
| O: 0.56%
H: 0.49%
C: -0.12%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AZN | $68.53 0.39% 0.39% 3.2M
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.75%
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
disease report treatment expansion global infections market
Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million from 2023 to 2028, North America to account for 42% of market growth - Technavio
Published: 2023-12-07 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 2.06%
H: 0.82%
C: 0.82%
ELDN | $1.57 -1.88% 3.03% 13K
|
Manufacturing
|
| O: -1.59%
H: 7.26%
C: 2.42%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
DNLI | $16.82 -3.0% -3.15% 960K
|
Health Technology
|
| O: -0.21%
H: 0.08%
C: -1.76%
BCLI | $0.5408 2.6% 2.73% 520K
|
Health Technology
|
| O: 0.0%
H: 3.56%
C: -9.77%
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.61%
H: 1.33%
C: 0.69%
america sclerosis treatment growth market
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
Published: 2023-07-19 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.4%
H: 0.68%
C: -1.19%
conference association biomarker alzheimer’s international
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-07-07 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.21%
H: 0.34%
C: -3.68%
leqembi fda disease approval treatment alzheimer's grants
EISAI PUBLISHES LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Published: 2023-04-03 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.08%
H: 0.17%
C: -0.67%
health lecanemab therapy
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
Published: 2023-03-30 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.11%
H: 1.29%
C: 0.94%
lecanemab meeting
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Published: 2023-03-30 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.11%
H: 1.29%
C: 0.94%
lecanemab study phase 2
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Published: 2023-03-19 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.57%
H: 1.56%
C: 1.23%
lecanemab therapy
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Published: 2023-03-05 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.09%
H: 0.79%
C: -0.09%
treatment fda disease application grants license approval alzheimer’s review
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Published: 2023-02-27 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.53%
H: 1.02%
C: 0.78%
lecanemab medical application license review china
Lecanemab Receives Priority Review Status in Japan
Published: 2023-01-29 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: -0.52%
lecanemab japan review
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Published: 2023-01-26 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.15%
H: 1.21%
C: -0.78%
treatment lecanemab disease application alzheimer’s authorization
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE
Published: 2023-01-10 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.14%
H: 1.23%
C: 1.13%
treatment europe lecanemab disease alzheimer's application authorization
EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
Published: 2022-12-22 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -0.46%
china submission lecanemab
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
Published: 2022-12-15 (Crawled : 00:00) - globenewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -1.02%
H: 1.79%
C: 1.58%
Addisons disease therapeutics market size to increase by USD 442 million: 41% growth to originate from North America - Technavio
Published: 2022-12-14 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 290
|
Health Technology
|
| O: -1.57%
H: 2.23%
C: 2.23%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
GSK | $39.6 -0.88% 0.03% 2.6M
|
Health Technology
|
| O: 0.36%
H: 0.28%
C: -1.17%
ABT | News | $105.9 -3.03% 0.38% 11M
|
Health Technology
|
| O: -1.27%
H: 0.14%
C: -1.21%
TECH | $62.73 -2.0% -2.09% 900K
|
Health Technology
|
| O: -1.84%
H: 0.92%
C: -1.2%
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: -0.51%
H: 0.11%
C: -1.44%
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
|
| O: -0.25%
H: 0.25%
C: -1.59%
america disease therapeutics growth market
Biosimilars market size to increase by USD 42,227.12 million: Europe to contribute 46% of market growth - Technavio
Published: 2022-12-08 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.55%
H: 0.39%
C: 0.39%
VTRS | $11.1 -0.18% -0.23% 4.7M
|
Health Technology
|
| O: 0.0%
H: 0.82%
C: -1.64%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.24%
H: 0.32%
C: -0.93%
ABBV | $164.25 1.05% 0.26% 3M
|
Health Technology
|
| O: 0.46%
H: 0.59%
C: -2.22%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.0%
H: 1.34%
C: -1.29%
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
|
| O: -0.48%
H: 0.35%
C: -1.95%
europe growth market
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE
Published: 2022-09-27 (Crawled : 00:00) - prnewswire.com
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 43.06%
H: 0.17%
C: -2.24%
global disease alzheimer's study lecanemab
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.